MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Cogent Biosciences, Inc. (COGT)

Cogent Biosciences, Inc. (COGT)

|||

Cash Flow Overview

Change in Cash
-$60,036K
Free Cash flow
-$77,641K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities and sales of marketab...
    • Accrued expenses and other curre...
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accounts payable
    • Net amortization (accretion) of ...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-96,405
-97,352
-102,492
-80,930
Depreciation and amortization expense
741
-1,310
-
641
Depreciation expense
-
-
2,564
-
Stock-based compensation expense
17,107
16,908
15,751
10,604
Amortization of operating leases, right-of-use assets
628
529
513
506
Change in fair value of cvr liability
-
-
0
-
Net amortization (accretion) of premiums (discounts) on marketable securities
961
1,180
1,056
167
Amortization of debt discount and issuance costs
284
278
238
300
Loss on debt extinguishment
-
-
-7,181
-
Loss on fixed asset disposal
1
-135
0
-
Prepaid expenses and other current assets
-297
1,835
3,236
-806
Other assets
-1
-1,361
-1,187
-374
Accounts payable
-6,256
4,240
-6,525
-596
Accrued expenses and other current liabilities
7,617
-10,200
9,100
4,565
Operating lease liability
-351
-422
-407
-400
Other liabilities
28
29
13
11
Net cash used in operating activities
-77,271
-86,883
-79,105
-64,286
Purchases of property and equipment
370
449
811
65
Purchases of marketable securities
82,806
133,839
395,222
224,066
Maturities and sales of marketable securities
97,456
97,831
73,264
69,085
Net cash (used in) provided by investing activities
14,280
-36,457
-322,769
-155,046
Proceeds from long-term debt
0
-
0
0
Repayment of long-term debt
-
-
54,635
-
Proceeds from convertible senior notes
-
-
223,100
-
Payment of debt issuance costs
0
-
318
235
Proceeds from issuance of common stock in public offerings, net of offering costs-IPOOne
-
-
539,776
-
Proceeds from issuance of common stock in public offerings, net of offering costs-IPOTwo
-
-
0
-
Proceeds from issuance of common stock under atm, net of issuance costs of 1.4 million and 0.7 million, respectively
0
45,712
135,073
0
Proceeds from issuance of common stock in public offering, net of offering costs of 14.3 million
-
-
-
215,792
Proceeds from issuance of common stock and series b non-voting convertible preferred stock in connection with the private placement, net of offering costs 11.7 million
-
-
0
0
Taxes paid related to net share settlement of equity awards
-
-
48,896
-
Proceeds from pre-funded warrant exercises
0
6
-
-
Proceeds from issuance of common stock upon stock option exercises
2,955
5,756
10,361
1,044
Proceeds from issuance of common stock from employee stock purchase plan
0
1,062
0
766
Net cash provided by financing activities
2,955
52,536
588,669
217,367
Net (decrease) increase in cash, cash equivalents and restricted cash
-60,036
-70,804
186,795
-1,965
Cash, cash equivalents and restricted cash at beginning of period
241,624
312,428
125,633
98,165
Cash, cash equivalents and restricted cash at end of period
181,588
241,624
312,428
125,633
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities and sales ofmarketable securities$97,456K (-33.64%↓ Y/Y)Proceeds from issuance ofcommon stock upon stock...$2,955K (1995.74%↑ Y/Y)Net cash (used in)provided by investing...$14,280K (-81.76%↓ Y/Y)Net cash provided byfinancing activities$2,955K (-95.91%↓ Y/Y)Canceled cashflow$83,176K Net (decrease)increase in cash, cash...-$60,036K (-303.98%↓ Y/Y)Canceled cashflow$17,235K Stock-based compensationexpense$17,107K (-13.27%↓ Y/Y)Accrued expenses andother current...$7,617K (355.69%↑ Y/Y)Depreciation andamortization expense$741K (-42.78%↓ Y/Y)Amortization of operatingleases, right-of-use...$628K (-37.20%↓ Y/Y)Prepaid expenses andother current assets-$297K (86.71%↑ Y/Y)Amortization of debt discountand issuance costs$284K (350.79%↑ Y/Y)Other liabilities$28K (211.11%↑ Y/Y)Other assets-$1K Purchases of marketablesecurities$82,806K (21.98%↑ Y/Y)Purchases of property andequipment$370K (-45.43%↓ Y/Y)Net cash used inoperating activities-$77,271K (36.17%↑ Y/Y)Canceled cashflow$26,703K Net loss-$96,405K (33.75%↑ Y/Y)Accounts payable-$6,256K (-235.65%↓ Y/Y)Net amortization(accretion) of premiums...$961K (30.04%↑ Y/Y)Operating lease liability-$351K (53.69%↑ Y/Y)Loss on fixed assetdisposal$1K